Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy-Reference-Cited by-同舟云学术

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Published:2016-12-22 Issue:6 Volume:37 Page:827-835
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Lim Lucy¹²³⁴,Thompson Alexander²³⁴,Patterson Scott¹,George Jacob⁵,Strasser Simone⁶,Lee Alice⁷,Sievert William⁸,Nicoll Amanda⁹¹⁰,Desmond Paul²⁴,Roberts Stuart¹¹,Marion Kaye¹²,Bowden Scott³,Locarnini Stephen³⁴,Angus Peter¹⁴

Affiliation:

1. Liver Transplant & Gastroenterology Department; Austin Health; Melbourne VIC Australia

2. Gastroenterology Department; St Vincent's Hospital; Melbourne VIC Australia

3. Molecular Research & Development Laboratory; Victorian Infectious Diseases Reference Laboratory; Melbourne VIC Australia

4. University of Melbourne; Melbourne VIC Australia

5. Storr Liver Centre; Westmead Millennium Institute for Medical Research; Westmead Hospital & University of Sydney; Sydney NSW Australia

6. AW Morrow Gastroenterology & Liver Centre; Royal Prince Alfred Hospital; Camperdown NSW Australia

7. Gastroenterology Department; Concord Hospital; Sydney NSW Australia

8. Gastroenterology Department; Monash Medical Centre; Melbourne VIC Australia

9. Gastroenterology & Hepatology Department; Royal Melbourne Hospital; Melbourne VIC Australia

10. Gastroenterology Department; Eastern Health; Melbourne VIC Australia

11. Gastroenterology Department; Alfred Hospital; Melbourne VIC Australia

12. Mathematical & Geospatial Sciences Department; RMIT University; Melbourne VIC Australia

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13331/fullpdf

Reference21 articles.

1. Present and future therapies of hepatitis B: from discovery to cure;Liang;Hepatology,2015

2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

3. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013;Schweitzer;Lancet,2015

4. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B;Chang;J Gastroenterol Hepatol,2004

5. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years;Hadziyannis;Gastroenterology,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir;Journal of Clinical Virology;2024-10

2. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) genotypic resistance in people treated with entecavir or tenofovir;2023-11-09

3. Current Status of Drug Therapy for Chronic Hepatitis B;Advances in Clinical Medicine;2022

4. Abstracts;Liver International;2019-11-27

5. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance;Liver International;2019-10-21